Skip to contents

Mark A. Perrella, MD
Associate Physician, Brigham and Women's Hospital
Associate Professor of Medicine, Harvard Medical School

Brigham and Women's Hospital
Department of Medicine
Department of Newborn Medicine
75 Francis Street
Boston, MA 02115

Edit Profile

Research Narrative:

Dr. Perrella is an Associate Professor of Medicine at Harvard Medical School and an Associate Physician in the Pulmonary and Critical Care Division at Brigham and Women’s Hospital in Boston, MA. Previously he was an Assistant Professor of Medicine at Harvard Medical School and Harvard School of Public Health, within the Center for Prevention of Cardiovascular Diseases under the directorship of Dr. Edgar Haber. While at Harvard, his molecular biology training came in the Laboratory of Dr. Arthur Mu-En Lee. Prior to this, Dr. Perrella was an Instructor in Medicine at the Mayo Clinic in Rochester, MN where he completed his Internal Medicine training, Pulmonary fellowship, and research training in the laboratory of Dr. John C. Burnett, Jr. Dr. Perrella received his M.D. degree from the University of Nebraska. Dr. Perrella has received a number of honors and awards throughout his career including the Internal Medicine Outstanding Achievement Award at the Mayo Graduate School of Medicine; Mayo Foundation Scholar in the Division of Thoracic Diseases and Internal Medicine; Mayo Alumni Association’s Donald C. Balfour Award for Meritorious Research; and the Mayo Foundation Clinician Scholar Award. Dr. Perrella is an National Institutes of Health (NIH) funded investigator, and he is devoted to the scientific peer review process including is involvement in serving NIH study sections and his appointment as Deputy Editor of the American Journal of Respiratory Cell and Molecular Biology.

The Perrella laboratory is interested in two areas of investigation:

  • Regulation of genes important for the modulation of vascular tone, vascular cell growth, and oxidative stress in inflammatory disease processes involving the lungs and other critical organs. Using cellular and molecular techniques, they are elucidating the importance of heme oxygenase-1 and nitric oxide synthase 2 in endotoxemia, ischemia/reperfusion injury, adult respiratory distress syndrome, hypertension (pulmonary and systemic), and atherosclerosis – diseases in which excellent animal models have been developed. By investigating the molecular mechanisms regulating genes important in the pathogenesis of these detrimental disease processes, the Perrella laboratory hopes to identify targets for more effective therapy.
  • Investigate the regulation and biology of genes selectively expressed in vascular smooth muscle cells. The regulation of these genes at the transcriptional level is being studied to determine why cell-type selective expression occurs, and this information is used to target gene expression in vivo. In performing these studies, transgenic and knockout mice are generated in the Perrella laboratory, and studies are being performed in various animal models of disease.

University of Nebraska, College of Medicine , 1986, MD

Publications (Pulled from Harvard Catalyst Profiles):

1. Tsoyi K, Osorio JC, Chu SG, Fernandez IE, De Frias SP, Sholl L, Cui Y, Tellez CS, Siegfried JM, Belinsky SA, Perrella MA, El-Chemaly S, Rosas IO. Lung Adenocarcinoma Syndecan-2 Potentiates Cell Invasiveness. Am J Respir Cell Mol Biol. 2019 Jun; 60(6):659-666.

2. Stump B, Shrestha S, Lamattina AM, Louis PH, Cho W, Perrella MA, Ai X, Rosas IO, Wagner FF, Priolo C, Astin J, El-Chemaly S. Glycogen synthase kinase 3-ß inhibition induces lymphangiogenesis through ß-catenin-dependent and mTOR-independent pathways. PLoS One. 2019; 14(4):e0213831.

3. Fredenburgh LE, Perrella MA, Barragan-Bradford D, Hess DR, Peters E, Welty-Wolf KE, Kraft BD, Harris RS, Maurer R, Nakahira K, Oromendia C, Davies JD, Higuera A, Schiffer KT, Englert JA, Dieffenbach PB, Berlin DA, Lagambina S, Bouthot M, Sullivan AI, Nuccio PF, Kone MT, Malik MJ, Porras MAP, Finkelsztein E, Winkler T, Hurwitz S, Serhan CN, Piantadosi CA, Baron RM, Thompson BT, Choi AM. A phase I trial of low-dose inhaled carbon monoxide in sepsis-induced ARDS. JCI Insight. 2018 12 06; 3(23).

4. Shu C, Huang H, Xu Y, Rota M, Sorrentino A, Peng Y, Padera RF, Huntoon V, Agrawal PB, Liu X, Perrella MA. Pressure Overload in Mice With Haploinsufficiency of Striated Preferentially Expressed Gene Leads to Decompensated Heart Failure. Front Physiol. 2018; 9:863.

5. Baron RM, Kwon MY, Castano AP, Ghanta S, Riascos-Bernal DF, Lopez-Guzman S, Macias AA, Ith B, Schissel SL, Lederer JA, Reeves R, Yet SF, Layne MD, Liu X, Perrella MA. Frontline Science: Targeted expression of a dominant-negative high mobility group A1 transgene improves outcome in sepsis. J Leukoc Biol. 2018 10; 104(4):677-689.

6. Huntoon V, Widrick JJ, Sanchez C, Rosen SM, Kutchukian C, Cao S, Pierson CR, Liu X, Perrella MA, Beggs AH, Jacquemond V, Agrawal PB. SPEG-deficient skeletal muscles exhibit abnormal triad and defective calcium handling. Hum Mol Genet. 2018 05 01; 27(9):1608-1617.

7. Ghanta S, Kwon MY, Rosas IO, Liu X, Perrella MA. Mesenchymal Stromal Cell Therapy: Does the Source Matter? Crit Care Med. 2018 02; 46(2):343-345.

8. Tsoyi K, Chu SG, Patino-Jaramillo NG, Wilder J, Villalba J, Doyle-Eisele M, McDonald J, Liu X, El-Chemaly S, Perrella MA, Rosas IO. Syndecan-2 Attenuates Radiation-induced Pulmonary Fibrosis and Inhibits Fibroblast Activation by Regulating PI3K/Akt/ROCK Pathway via CD148. Am J Respir Cell Mol Biol. 2018 02; 58(2):208-215.

9. Kwon MY, Hwang N, Park YJ, Perrella MA, Chung SW. NOD2 deficiency exacerbates hypoxia-induced pulmonary hypertension and enhances pulmonary vascular smooth muscle cell proliferation. Oncotarget. 2018 Feb 27; 9(16):12671-12681.

10. Yun JH, Morrow J, Owen CA, Qiu W, Glass K, Lao T, Jiang Z, Perrella MA, Silverman EK, Zhou X, Hersh CP. Transcriptomic Analysis of Lung Tissue from Cigarette Smoke-Induced Emphysema Murine Models and Human Chronic Obstructive Pulmonary Disease Show Shared and Distinct Pathways. Am J Respir Cell Mol Biol. 2017 07; 57(1):47-58.